Zai Lab Sequential Product Growth Cools After KarXT Launch

The Tip Desk · November 11, 2026 · 3 min read

Third-quarter total revenue was $108.2 million as net product sales rose 2% from the prior quarter, a slower pace than the 11% sequential gain in the second quarter.

Zai Lab Limited (ZLAB), an innovation-driven global biopharmaceutical company, reported third-quarter 2026 total revenue of $108.2 million, compared with $116.1 million a year earlier. Net product revenue was $107.6 million.

Sequential product sales rose 2% versus the second quarter, a sharp slowdown from the 11% sequential increase the company reported in that prior period. The company said the latest gain was driven by NUZYRA, supported by increased market coverage and penetration, and by KarXT, which launched in June 2026, partially offset by a decrease in OPTUNE due to evolving competition in the glioblastoma market.

Research and development expenses were $49.8 million, versus $47.9 million a year earlier. Selling, general and administrative expenses were $70.1 million in both the third quarter of 2026 and the same period in 2025. The company said both lines remained relatively flat year over year as it continued efforts to streamline the organization and optimize resource allocation.

Loss from operations was $63.0 million, or $47.6 million when adjusted to exclude depreciation, amortization, and share-based compensation. Net loss was $46.1 million, or $0.04 a share ($0.41 an ADS), compared with a net loss of $36.0 million a year earlier, or $0.03 a share ($0.33 an ADS). The company said the increase in net loss was primarily due to $13.6 million of inventory write-downs in 2026.

Cash and cash equivalents, current restricted cash, and short-term investments totaled $659.7 million as of September 30, 2026, compared with $717.5 million as of June 30, 2026.

On October 22, 2026, after quarter-end, Zai Lab sold 11,340,000 ADSs at $22.04 per ADS in a private placement that closed October 27, raising about $250.0 million gross and about $241.2 million net. The company said it intends to use the net proceeds to fund pipeline development and for working capital and other general corporate purposes.

The company presented first-line small-cell lung cancer data at ESMO in October. In the ongoing Phase 1 study, zocilurtatug pelitecan (zoci) 1.6 mg/kg plus atezolizumab achieved a confirmed objective response rate of 81.8% and an estimated six-month progression-free survival rate of 81.9% among 33 efficacy-evaluable patients. Grade 3 or higher adverse events attributed to zoci occurred in 9.1% of patients. Zai Lab said it is advancing the doublet into a global Phase 3 study in first-line extensive-stage SCLC, with initiation targeted by year-end 2026.

Enrollment was completed in zoci’s potentially registrational second-line extrapulmonary neuroendocrine carcinomas expansion cohort, with topline data expected in the first half of 2027 and a potential U.S. accelerated-approval BLA thereafter. The DLLEVATE Phase 3 in second-line-plus SCLC is ongoing, with a potential interim analysis in the second half of 2027.

ZL-1503, a long-acting IL-13/IL-31Rα bispecific antibody, is advancing toward first-in-human data at ACAAI in November 2026 and atopic dermatitis patient data in the first half of 2027. The company said it expects two additional oncology and immunology programs to enter the clinic in 2027.

Partner argenx announced it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in moderate-to-severe Sjögren’s disease after an independent data monitoring committee recommended stopping for futility. In August, argenx reported that Phase 3 ALKIVIA in autoimmune myositis met its primary endpoint.

Zai Lab said it is positioned for a return to meaningful growth in 2027 as patient access expands for key products, and that its commercially profitable China business is expected to return to growth in 2027.